Retatrutide is not suitable for individuals with allergic reactions to peptides, pregnant women, or those with pre-existing metabolic conditions without proper medical supervision
SURMOUNT-1 Trial (72-Week Duration, 2,539 Participants): Average weight loss with 15 mg: 20.9% of body weight Participants losing 5%: 91% Participants losing 10%: 82% Participants losing 20%: 57% SURMOUNT-2 Trial (People with Type 2 Diabetes): Average weight loss with 15 mg: 15.7% A1C reduction: 2.0 percentage points Source: Jastreboff AM, et al
80.Jabczyk, M., Nowak, J., Hudzik, B., and Zubelewicz-Szkodziska, B
Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA (2024) Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide